Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA
Glenmark’s Ryaltris nasal spray, using Aptar Pharma’s VP3 nasal spray system, treats nasal and ocular symptoms.
Stay updated with breaking news from Aptar Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Glenmark’s Ryaltris nasal spray, using Aptar Pharma’s VP3 nasal spray system, treats nasal and ocular symptoms.
The development of a protein vaccine candidate for nasal administration has taken another step. Led by the BioMAP research team, from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours, this project, supported by the Ministry of Higher Education, Research and Innovation, and accompanied by the ANRS | Maladies infectieuses émergentes, is moving up a gear.
New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray SystemCrystal Lake, Illinois, January 27, 2022 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multido...
Voluntis and AliveCor Partner to Advance Management of Atrial Fibrillation for Patients with CancerCambridge, Massachusetts and Mountain View, California, January 6, 2022 - Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced that it has entered into a partnership agreement with Aliv...
Join this webinar to discover more about these scientific guidelines and how Aptar Pharma's innovative devices for non-clinical research can meet unmet pharmaceutical needs and... | December 16, 2021